Instead of a traditional chemotherapy comparison, Divarasib's registrational study is a head-to-head trial against approved KRAS G12C inhibitors. This trial design reflects a strategic shift towards proving superiority within a new drug class, not just efficacy against older standards of care.

Unlike earlier G12C-specific "RAS-off" drugs that lock KRAS in an inactive state, new "RAS-on" inhibitors form a tri-complex with an active form of RAS and an endogenous protein. This novel mechanism enables targeting of a much broader spectrum of RAS mutations, representing a significant breakthrough for treating pancreatic cancer.

The focus on KRAS is expanding beyond small molecule inhibitors to diverse immunotherapies. Approaches like TCR T-cells, mRNA vaccines targeting KRAS neoepitopes, and novel amphiphil vaccines are being developed to activate a patient's immune system against their specific cancer mutations.

A new class of drugs, "RAS on" inhibitors (e.g., daxorarasib), targets the active, GTP-bound state of KRAS. This mechanism is distinct from first-generation "RAS off" inhibitors (e.g., sotorasib) and is designed to treat patients who develop resistance, offering a subsequent line of targeted therapy.

In frontline clinical trials for KRAS G12C NSCLC, combining olomorasib with pembrolizumab alone yielded a 90% response rate in patients with >50% PD-L1 expression. This surpassed the 78% rate seen when chemotherapy was added, suggesting a more targeted approach may be superior for this specific biomarker-defined subgroup.

The next therapeutic frontier for RAS-mutated cancers involves combining multi-selective RAS inhibitors (e.g., daraxonrasib) with mutation-specific inhibitors (e.g., zoldon-rasib). This dual-pronged strategy aims to achieve deeper and more durable pathway inhibition by attacking the target through different mechanisms simultaneously.

The KRAS G12D mutation, unlike the more common G12C, often occurs in younger, never-smoking lung cancer patients who previously lacked targeted therapy options. The high response rate (61%) and good tolerability of the G12D inhibitor Zoldanrasib could fill a significant unmet need in this specific demographic.

The success of KRAS-G12C inhibitors in lung cancer catalyzed a surge of interest and investment in pancreatic cancer, a historically challenging field. This has spurred new approaches, including pan-KRAS inhibitors and novel modalities like antibody-drug conjugates (ADCs), driven by the belief that the notoriously difficult disease is now druggable.

In the rare scenario of colorectal cancer with both HER2 amplification and a KRAS G12C mutation, US-based experts might prioritize KRAS-directed therapy. This preference is driven by durable data for KRAS inhibitors, even though choosing between targets is difficult without direct comparative studies.